PHOENIX failed primary; Relyvrio voluntarily withdrawn April 2024. Triggered post-hoc reflection on Phase 2 effect-size inflation.
Details
- nct_id
- NCT05021536
- phase
- phase_3
- status
- completed
- domain
- als
- indication
- ALS (no genetic stratification)
- intervention
- AMX0035 (sodium phenylbutyrate + taurursodiol)
- sponsor
- Amylyx
- n_enrolled
- 664
- primary_endpoint
- ALSFRS-R change at 48 weeks
Raw fields (1)
- metadata
{}